Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9179 USD | +2.10% | +13.87% | +13.32% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.32% | 90.83M | |
+29.68% | 681B | |
+21.79% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+13.77% | 235B | |
+4.47% | 199B | |
-12.39% | 189B | |
-3.79% | 157B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- HC Wainwright Adjusts HOOKIPA Pharma Price Target to $6.50 From $8, Maintains Buy Rating